Indian Deeptech Founders Question Venture Capital Risk Appetite

Following Skyroot Aerospace's successful orbital launch in July 2026, a debate has intensified regarding the capability of India’s venture capital ecosystem to support high-risk hardware and scientific startups. Journalist Ashlee Vance recently highlighted a perceived reluctance among local investors to fund early-stage ventures that lack immediate commercial traction, echoing concerns voiced by several local entrepreneurs.

Founders, including those in the medical technology sector, report that local investors often demand existing revenue streams before committing capital, a requirement that complicates development for firms requiring lengthy clinical validation or regulatory testing. Critics argue that this conservative approach forces startups to prioritize short-term commercial metrics over the long-term R&D necessary for foundational technology.

Data from Inc42 reveals a shift in the investment landscape. While deeptech funding rose by 176% year-over-year in Q3 2026 to $290 million, the capital was highly concentrated, with a single deal accounting for approximately one-third of the total. This concentration of funds into fewer, more established firms suggests that despite rising investment totals, the ecosystem remains cautious regarding unproven scientific experiments.